CNS RELAPSE OF DIFFUSE LARGE B‐CELL LYMPHOMA AND ROLE OF UPFRONT PROPHYLAXIS: A 10‐YEAR SINGLE CENTER EXPERIENCE.

In univariate analysis CNS relapse risk was significantly influenced by ECOG PS and elevated LDH levels, while the use of prophylaxis was not shown to impact the risk of CNS recurrence. 95/397 pts received CNS prophylaxis (24%): 59 by intrathecal (IT) route only (15%) ( I n i 26 CNS-IPI 2-3; I n i 29 CNS-IPI 4-6), 25 by iv MTX only (6%) ( I n i 17 HD-MTX >=3 g/mq; n 6 CNS-IPI 2-3; I n i 16 CNS-IPI 4-6), and 11 by combined route (3%) ( I n i 5 CNS-IPI 2-3, I n i 6 CNS-IPI 3-6). 12 pts experienced CNS relapse; 8/12 exclusively CNS and 4/12 along with systemic recurrence. B Introduction: b Central nervous system (CNS) relapse of diffuse large B-cell lymphoma (DLBCL) is a rare event, occurring in about 5% of patients (pts) and correlating with a very dismal prognosis. [Extracted from the article]